AD

Aarey Drugs & Pharmaceuticals Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Aarey Drugs & Pharmaceuticals Q2 Results 2026: PAT ₹1 Cr +34%

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Revenue
₹89Cr
+5.3% YoY
+98.6% QoQ
Net profit
₹1Cr
+34.3% YoY
+34.3% QoQ
Margin
2.4%
−0.7 pp YoY
−0.6 pp QoQ

Aarey Drugs & Pharmaceuticals Ltd Q2 FY27 key numbers

Revenue
Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs.

As stated in Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 results statement · published 15 Nov 2026. Reported figures, not investment advice.

Based on Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹115
Market cap₹367 Cr
P/E88.0

The short version

Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs. EBITDA (Profit Before Exceptional Items and Tax + Depreciation + Finance Cost):.

From Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.

How did Aarey Drugs & Pharmaceuticals' revenue grow in the September 2026 quarter?

- Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs - Revenue from Operations for quarter ended 30.09.2025: ₹841.62 Lakhs - Year-on-year revenue growth: Approximately 240% increase (from ₹841.62 Lakhs to ₹2,865.24 Lakhs) All figures are as per the unaudited financial results disclosed for the quarter ended September 30, 2026.

What happened to Aarey Drugs & Pharmaceuticals' margins in Q2 FY27?

EBITDA (Profit Before Exceptional Items and Tax + Depreciation + Finance Cost):

Locked: what Aarey Drugs & Pharmaceuticals Ltd said on margins

Also locked on this page: fundraising, order book

Free account, 30 seconds. No card needed.

What capex is Aarey Drugs & Pharmaceuticals planning?

  • The company purchased fixed assets during the reporting period; however, these assets are not yet ready for their intended use as of period end (Sep 30, 2026) - no depreciation charged yet. Depreciation to commence once assets are fully installed and commissioned (Page 8, 4).
  • Capital work-in-progress as of Sep 30, 2026 is ₹235.70 lakhs, decreased from ₹811.58 lakhs as of March 31, 2026 (Page 5).
  • Funds raised through preferential issue of convertible warrants (₹3190 lakhs) are proposed to be used partly for augmentation of funding needs, repayment/presentment of liabilities/debts, investment in technology or general corporate purposes to enhance business (Page 15).
  • As of Sep 30, 2026, ₹900 lakhs of funds from warrants remain unutilized and are pending utilization for stated objects (Page 15).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Aarey Drugs & Pharmaceuticals raising money or cutting debt?

The presentation mentions fundraising through the issuance of Convertible Warrants on a preferential…

Locked: what Aarey Drugs & Pharmaceuticals Ltd said on fundraising

Also locked on this page: margins, order book

Free account, 30 seconds. No card needed.

How big is Aarey Drugs & Pharmaceuticals' order book?

See what Aarey Drugs & Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

Aarey Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Aarey Drugs & Pharmaceuticals Ltd Q2 FY27 results — key figures

Aarey Drugs & Pharmaceuticals Ltd Q2 FY27 reported results vs Q2 FY26, ₹ crore
₹ CrQ2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue8984+5.3%45+98.6%
Operating profit (EBITDA)23-18.9%1+60.9%
Operating margin2.4%3.1%-0.7 pp3%-0.6 pp
Profit before tax21+12.2%1+219.2%
Net profit (PAT)11+34.3%1+34.3%
EPS (₹)0.430.72-40.3%0.36+19.4%

Source: Aarey Drugs & Pharmaceuticals Ltd's results filing to NSE (standalone), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹89 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

Others in Pharmaceuticals & Biotechnology this season

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

  • Alpa Laboratorie (Q2 FY27)

    Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Aarey Drugs & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Aarey Drugs & Pharmaceuticals Ltd Q2 FY27 results?

Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs. EBITDA (Profit Before Exceptional Items and Tax + Depreciation + Finance Cost):.

What is Aarey Drugs & Pharmaceuticals Ltd share price analysis?

Aarey Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 88.0 with a market cap of ₹367 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aarey Drugs & Pharmaceuticals Ltd planning capital expenditure?

The company purchased fixed assets during the reporting period; however, these assets are not yet ready for their intended use as of period end (Sep 30, 2026) - no depreciation charged yet.

Keep Aarey Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.